Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Dec

Today In Oncology

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

David A. Hyman, MD, JD, on Inclusive Shared Savings

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

My Cancer Diagnosis and Renewed Commitment to Fight for Patients

Geriatric Surgery Verification Program May Improve Outcomes in Older Patients With Cancer in Community Hospitals

Trastuzumab Deruxtecan vs Chemotherapy in Advanced Breast Cancer

Adjuvant Tamoxifen May Reduce Recurrence Risk for Patients With ‘Good-Risk’ DCIS Who Forgo Radiation

Most Patients With Intermediate-Risk Breast Cancer May Safely Avoid Chest Wall Irradiation After Mastectomy